Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review
- PMID: 38978028
- PMCID: PMC11229247
- DOI: 10.1186/s13023-024-03265-z
Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review
Abstract
Background: This systematic study aims to assess the global epidemiologic, economic, and humanistic burden of illness associated with all types of hereditary angioedema.
Methods: A systematic search for articles reporting the epidemiologic, economic, and humanistic burden associated with patients with HAE was conducted using English and Chinese literature databases from the inception to May 23, 2022. The selected studies were assessed for their quality and risk of bias. The study was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses and registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD42022352377).
Results: In total, 65 articles that met the search inclusion criteria reported 10,310 patients with HAE, of whom 5861 were female patients. Altogether, 4312 patients (81%) and 479 patients (9%) had type 1 and type 2 HAE, respectively, whereas 422 patients (8%) had HAE-normal C1-INH. The overall prevalence of all types of HAE was between 0.13 and 1.6 cases per 100,000. The mean or median delay from the first onset of a symptom of HAE to confirmed diagnosis ranged from 3.9 to 26 years. The estimated risk of death from asphyxiation was 8.6% for patients with HAE. Hospitalization, medication, unnecessary surgeries, doctor visits, specialist services, and nursing costs are direct expenses that contribute to the growing economic burden. The indirect cost accounted mostly due to missing work ($3402/year) and loss of productivity ($5750/year). Furthermore, impairment of QoL as reported by patient-reported outcomes was observed. QoL measures identified depression, anxiety, and stress to be the most common symptoms for adult patients and children.
Conclusion: This study highlights the importance of early diagnosis and the need for improving awareness among health care professionals to reduce the burden of HAE on patients and society.
Keywords: Autosomal disorder; Clinical burden; Economic cost; Hereditary angioedema; Quality of life.
© 2024. The Author(s).
Conflict of interest statement
Yanan Sheng, Miao He, and Tianxiang Chen are employees of Takeda (China) International Trading Co. Ltd. The other authors have no conflicts of interest to declare.
Figures
Similar articles
-
Interventions for the long-term prevention of hereditary angioedema attacks.Cochrane Database Syst Rev. 2022 Nov 3;11(11):CD013403. doi: 10.1002/14651858.CD013403.pub2. Cochrane Database Syst Rev. 2022. PMID: 36326435 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2. Cochrane Database Syst Rev. 2020. PMID: 33075160 Free PMC article.
-
Supported self-management for patients with moderate to severe chronic obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis.Health Technol Assess. 2015 May;19(36):1-516. doi: 10.3310/hta19360. Health Technol Assess. 2015. PMID: 25980984 Free PMC article.
-
Home treatment for mental health problems: a systematic review.Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150. Health Technol Assess. 2001. PMID: 11532236
Cited by
-
Reductions in medical visits and hospitalizations following berotralstat initiation in patients with hereditary angioedema in the United States.J Manag Care Spec Pharm. 2025 Jun;31(6):578-589. doi: 10.18553/jmcp.2025.31.6.578. J Manag Care Spec Pharm. 2025. PMID: 40443005 Free PMC article.
-
De Novo or inherited: gonosomal mosaicism in hereditary angioedema due to C1 inhibitor deficiency.Front Immunol. 2025 Feb 6;16:1550380. doi: 10.3389/fimmu.2025.1550380. eCollection 2025. Front Immunol. 2025. PMID: 39981253 Free PMC article.
-
Hereditary angioedema diagnosis: Reflecting on the past, envisioning the future.World Allergy Organ J. 2025 May 14;18(6):101060. doi: 10.1016/j.waojou.2025.101060. eCollection 2025 Jun. World Allergy Organ J. 2025. PMID: 40487881 Free PMC article. Review.
-
N-glycosylation in the SERPIN domain of the C1-esterase inhibitor in hereditary angioedema.JCI Insight. 2025 Jan 16;10(4):e185548. doi: 10.1172/jci.insight.185548. JCI Insight. 2025. PMID: 39823539 Free PMC article.
-
Dietary and physical trigger factors in hereditary angioedema: Self-conducted investigation and literature overview.Allergol Select. 2024 Nov 14;8:358-364. doi: 10.5414/ALX02523E. eCollection 2024. Allergol Select. 2024. PMID: 39564137 Free PMC article.
References
-
- Riedl MA, Lumry WR, Busse P, Levy H, Steele T, Dayno J, et al. Prevalence of hereditary angioedema in untested first-degree blood relatives of known subjects with hereditary angioedema. Allergy Asthma Proc. 2015;36:206–12. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405600/ Cited 2022 Sep 20. - PMC - PubMed
-
- Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. World Allergy Org J. 2022;15:100627. https://linkinghub.elsevier.com/retrieve/pii/S1939455122000035 Cited 2022 Sep 23. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous